(Q30760935)

26 June 2017

title

Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry (English)

1 reference

26 June 2017

1 reference

8

Buzdar AU

1 reference

26 June 2017

Esteva FJ

1

1 reference

26 June 2017

Hortobagyi GN

2

1 reference

26 June 2017

Sahin AA

3

1 reference

26 June 2017

Smith TL

4

1 reference

26 June 2017

Chin DM

5

1 reference

26 June 2017

Liang SY

6

1 reference

26 June 2017

Pusztai L

7

1 reference

26 June 2017

Bacus SS

9

1 reference

26 June 2017

publication date

1 January 2001

1 reference

Pathology Oncology Research

26 June 2017

published in

1 reference

26 June 2017

volume

7

1 reference

26 June 2017

issue

3

1 reference

26 June 2017

page(s)

171-177

1 reference

Expression of the ERBB3 gene product in breast cancer

26 June 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF03032345

Case-control differences in the reliability of reporting a history of induced abortion

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF03032345

ATM heterozygosity and breast cancer: screening of 37 breast cancer patients for ATM mutations using a non-isotopic RNase cleavage-based assay

21 January 2018

1 reference

12 December 2020

Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4

1 reference

12 December 2020

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

12 December 2020

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

12 December 2020

Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells

1 reference

12 December 2020

William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer

1 reference

12 December 2020

Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells

1 reference

12 December 2020

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications

1 reference

12 December 2020

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

1 reference

12 December 2020

Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt

1 reference

12 December 2020

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

12 December 2020

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis

1 reference

12 December 2020

Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response.

1 reference

12 December 2020

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

12 December 2020

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

1 reference

12 December 2020

Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors

1 reference

12 December 2020

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin

1 reference

12 December 2020

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways

1 reference

12 December 2020

Epidermal growth factor receptor and other oncogenes as prognostic markers

1 reference

12 December 2020

Growth factors in breast cancer

1 reference

12 December 2020

Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features

1 reference

12 December 2020

c-erbB-4 protein expression in human breast cancer

1 reference

12 December 2020

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis

1 reference

12 December 2020

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

1 reference

12 December 2020

Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.

1 reference

12 December 2020

Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells

1 reference

12 December 2020

Heregulin regulation of Akt/protein kinase B in breast cancer cells

1 reference

12 December 2020

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

1 reference

12 December 2020

The c-erbB3/HER3 receptor in human cancer.

1 reference

12 December 2020

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

1 reference

12 December 2020

Bivalence of EGF-like ligands drives the ErbB signaling network

1 reference

12 December 2020

Android obesity at diagnosis and breast carcinoma survival: Evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span,and survival from breast carcinoma

1 reference

12 December 2020

Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.

1 reference

12 December 2020

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03032345

1 reference

26 June 2017

1 reference